XML 30 R3.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Consolidated Statements of Net Loss and Comprehensive Loss - USD ($)
 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Expenses    
Sales and marketing $ 80,603 $ 7,029
Research and development 954,593 1,608,895
General and administrative 557,904 366,435
Professional and consulting fees 1,158,484 1,252,510
Loss before other items (2,751,584) (3,234,869)
Other items    
Other income 879,344  
Depreciation (240)  
Interest income 2,134 1,554
Interest expense (52,941)  
Foreign exchange gain (2,695) 26,912
Listing expense (41,481,605)  
Transaction expense (2,461,025)  
Gain on debt settlement 281,500  
Fair value loss on convertible note (5,157,397)  
Fair value loss on warrant liability (306,250)  
Fair value loss on promissory notes (108,288)  
NET LOSS (51,159,048) (3,206,403)
Other comprehensive income/(loss)    
Foreign exchange gain/(loss) on translation 3,715 (89,828)
Other comprehensive income 191,982  
TOTAL COMPREHENSIVE LOSS $ (50,963,351) $ (3,296,231)
Loss per share - basic (in dollars per share) $ (7.82) $ (0.66)
Loss per share - diluted (in dollars per share) $ (7.82) $ (0.66)
Weighted average number of outstanding shares - basic (in shares) 6,517,215 5,000,000
Weighted average number of outstanding shares - diluted (in shares) 6,517,215 5,000,000